Woman Man
- | Country :
- France
- | organs : -
- | Specialty : -
Extract
The objective of this randomized phase II is to evaluate the benefit of regorafenib for ovarian patients who reported a confirmed elevated CA-125 level under surveillance or bevacizumab, compared with tamoxifen.
Inclusion criteria
- Ovarian Carcinoma